• Candel Therapeutics posted a net loss of USD 8.86 million for the three months ended March 31, 2026, swinging from net income of USD 7.38 million a year earlier.
• Operating loss widened to USD 16.28 million as total operating expenses doubled to USD 16.28 million, led by research and development spending that more than doubled to USD 9.84 million.
• General and administrative costs climbed 56.64% to USD 6.44 million, including commercial readiness expense of USD 1.34 million.
• Cash and cash equivalents totaled USD 194.8 million at March 31, 2026; guidance said that balance should fund operations into first quarter 2028.
• Pipeline update reiterated plans to start a pivotal phase 3 NSCLC trial in second quarter 2026, target a BLA submission for aglatimagene in prostate cancer in fourth quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-222904), on May 14, 2026, and is solely responsible for the information contained therein.